

Original Research Article

Anti-ulcerogenic, antioxidant and mucogenic effects of L-cysteine in gastric tissue of wistar rats

ABSTRACT

Aim: to evaluate the effect of L-cysteine pretreatment on indomethacin induced ulceration in male wistar rats.

Study design: experimental animal study

Place and Duration of study: Department of Physiology (inflammation and Gastrointestinal secretion unit), College of Medicine, University of Ibadan, Nigeria, between January and July 2017.

Methodology: Fifty male wistar rats were used for this study and were randomly divided into two study groups of thirty five (25) animals each. The first sub-group was used for the anti-ulcer studies; antioxidant enzymes (SOD and MDA), Nitric oxide (NO), mean ulcer score and gastric blood flow (GBF), while the second sub-group was used for the gastric mucus secretion study. Each sub group was divided into five groups with five animals per group as follows: ulcer control, L-cysteine (100 mg/kg, 300 mg/kg and 500 mg/kg), cimetidine (50 mg/kg). Results were analyzed using ANOVA and reported as Mean \pm SEM. Values were considered significant at $P \leq 0.05$.

Results: The results of this study showed that L-cysteine (100mg, 300mg and 500mg respectively) pretreatment significantly reduced mean ulcer score (9.5 ± 1.9 ; 7.5 ± 1.5 ; 4.5 ± 0.9), and MDA level (7.2 ± 0.23 ; 7.49 ± 0.3 ; 6.54 ± 0.55) and increased SOD activity (10.69 ± 0.1 ;

Formatted: Underline

10.12±0.29; 14.76±0.07) when compared with the mean ulcer score, MDA and SOD in the ulcer control group (39.5±7.9; 10.62±1.11; 5.02±0.74). Also, NO level (10.8±0.44; 10.37±0.18; 8.41±0.06), gastric mucus secretion (0.92±0.008; 0.94±0.001; 0.99±0.001) and GBF (2.08±0.02; 2.11±0.06; 2.11±0.01) were significantly ($p<0.05$) higher in the L-cysteine pre-treated animals when compared with NO, mucus secretion and GBF in the ulcer control (7.86±0.09; 0.82±0.01).

Conclusion: This study shows that L-cysteine pre-treatment has anti-ulcer potential which might be mediated through increased antioxidant enzymes, increased mucus secretion and enhancing gastric blood flow. This will be of immense advantage in the treatment of peptic ulcer.

Keywords: L-cysteine, cimetidine, antioxidants, mucus secretion, anti-ulcer.

1. INTRODUCTION

Peptic ulcer, a common gastrointestinal disorder, is a multifactorial and complex disease that involves imbalance between gastric offensive factors (e.g. lipid peroxidation) and defensive mucosal factors e.g. antioxidant enzymes [1, 2]. However, diverse factors such as non-steroidal anti-inflammatory drugs (NSAIDs), stressful lifestyle, alcohol consumption, *Helicobacter pylori* (*H. pylori*) infection, smoking, and family history can contribute to its pathogenesis [3, 4]. [The](#) NSAIDs such as indomethacin are commonly prescribed drugs for the treatment of pain and inflammation in rheumatic disorders and osteoarthritis [5], but are associated with peptic ulcer as their major complications. The mechanisms underlying the pathogenesis of NSAIDs-induced ulcers are complex and multifactorial. It involves both prostaglandin-dependent (through Cyclooxygenase inhibition) and prostaglandin-independent mechanisms. The independent mechanisms include inflammatory, immunogenic, genetic, and stress response pathways [6].

48 In an attempt to protect the gastric mucosa from ulceration, enhance ulcer healing and
49 prevent ulcer recurrence, pharmacological control of gastric acid secretion has long
50 represented a desirable goal. Thus, there is an increasing need to develop more potent
51 therapeutic agents for the treatment of peptic ulcer and several experimental studies have
52 shown the effectiveness of some nutrients and food supplements in the management of peptic
53 ulcer.

54 L-cysteine is an essential amino acid that is ingested from diet to meet up the body's
55 requirement and is majorly found in most dairy foods (e.g. milk, egg, meat and spices). L-
56 cysteine contains sulfhydryl group and serve as a precursor of hydrogen sulphide [7].
57 Hydrogen sulphide is a potent mediator of vascular smooth muscle relaxation, exhibit anti-
58 inflammatory activities and contribute to gastric mucosal defense [8, 9]. It has also been
59 shown to reduce the severity of [NSAIDs](#) ~~non-steroidal anti-inflammatory drugs~~ and also
60 protective in a number of models of acute gastric injury, but the mechanism underlying this
61 action is unclear [10]. Therefore, the present study aimed at evaluating the mechanisms of
62 action of this amino acid in the prevention of peptic ulcer.

63 **2.0 MATERIALS AND METHODS**

64 **2.1 DRUGS AND CHEMICALS USED**

65 Cimetidine, Ulcertret-20 (Swiss pharma pvt.Ltd. 3709, GIDC, Phase IV, Vatva, Ahmedabad-
66 382 445, Gujarat, India. Indomethacin, Omecet (Medibios Laboratories PVT Limited. J-76,
67 M.I.D.C, Tarapur, Taluka-Palghar Dist, Thane-401 506, India), L-cysteine, (Solgar, Inc. 600
68 Willow Tree Road, Leonia, NJ 07605 U.S.A. Sodium thiopental (Abbot Laboratories),
69 Trichloroacetic acid (TCA), Thiobarbituric acid (TBA), Ellman reagent (5', 5' dithio-bis-2-
70 nitrobenzoic acid), Sodium azide, 1-2, 4-dinitrobenzene.

71 **2.2 Experimental [Design design](#)**

72 Fifty adult male Wistar rats weighing 100-130 g were used for this study. The animals were
73 obtained from Central Animal house, College of Medicine, University of Ibadan. The
74 experimental animals were acclimatized for two weeks and were fed on rats' pellets and
75 water given *ad libitum*. After the period of acclimatization, the experimental animals were
76 divided into two groups each containing twenty-five animals and each group were subdivided
77 into five groups containing five animals each and treated as follows; Group 1 (control) -
78 normal rats that had access to clean water and rat pellets; Group 2- animals pre-treated with
79 100 mg/kg body weight of L-cysteine; Group 3- animals pre-treated with 300 mg/kg body
80 weight of L-cysteine; Group 4- animals- pre-treated with 500 mg/kg body weight of L-
81 cysteine; group 5- animals pre-treated with 50 mg/kg body weight of cimetidine.
82 The first sub-group was used for the anti-ulcer studies; antioxidant enzymes (SOD and
83 MDA), Nitric oxide, Gastric blood flow and the mean ulcer score, while gastric mucus
84 secretion study was performed with the second sub-group. All procedures used in this study
85 conformed to the guidelines on the care and use of animals in research and teaching [11].

86 **2.3 Indomethacin Gastric Ulcer Induction**

87 Gastric ulcer was induced in the experimental animals using indomethacin at a dosage of 40
88 mg/kg body weight in accordance with previously described method by [12]. Afterwards, the
89 animals were sacrifice by cervical dislocation 4 hours after ulcer induction.

90 **2.4 Assessment of Ulcer Spots**

91 Macroscopic examination of the stomach was carried out and scored using the method
92 described by [13] modified by [14]. Ulcer index was calculated using the formula.

93
$$\text{Ulcer index} = \text{Mean Ulcer Score} \times \text{Number of animals in a group}/100$$

94 **2.5 Assay of Superoxide Dismutase (SOD)**

95 SOD activity was measured by assessing the inhibition of autoxidation of adrenaline at 30°C
96 with the pH raised from 7.8-10.2 using the method described by [15].

97 **2.6 Determination of Lipid Peroxidation ~~lipid peroxidation~~**

98 MDA (marker for oxidative stress) assessment was done according to the method of [16].
99 MDA which is the unit for lipid peroxidation is calculated in units/mg protein, using the
100 formula:

$$\begin{aligned} 101 \quad \text{MDA (units/mg proteins)} &= (\text{Absorbance} \times \text{Volume of mixture}) / (\text{E532nm} \times \text{Volume} \\ 102 \quad &\text{of sample} \times \text{mg protein}). \end{aligned}$$

103 **2.7 Gastric Mucus Secretion Study**

104 This study was carried out using the spectrophotometry method described by [17]. The
105 weight of dye was expressed over the weight of the stomach, to give the weight of mucus
106 secreted.

107 Thus,

$$\begin{aligned} 108 \quad \text{Gastric mucus secretion (mg/g tissue)} &= \frac{\text{Weight of dye (mg)}}{\text{Weight of stomach (g)}} \\ 109 \end{aligned}$$

110 **2.8 Determination on Nitric Oxide Levels**

111 Nitrite was determined as an oxidation product and indicator of NO synthesis as described by
112 [18]. The method is based on the addition of Griess reagent to the sample which converts
113 nitrite into deep purple azo chromophore. The colour intensity was measured using a UV-
114 visible spectrophotometer. Nitrite level was expressed as mol/g tissue.

115 **2.9 DETERMINATION OF GASTRIC BLOOD FLOW**

116 Gastric blood flow was measured as a component of abdominal aortic blood flow. Abdominal
117 aortic blood flow was measured by placing an ultrasonic Doppler flow probe
118 (Transonic# 11RB) around the abdominal aorta between the diaphragms and celiac artery.

119 Flow rates were obtained with the Transonic T206 Blood Flow Meter (Transonic Instrument,
120 Ithaca, NY).
121 Animals were fasted, but not deprived of water for 24 hours before the onset of the
122 experiment. 1 hour before ulcer induction, the test substance were administered to their
123 respective group after which indomethacin was given to induced ulcer in all groups except
124 group 1 (control group). Animals were anesthetized with ketamine (1ml/kg) intraperitoneal.
125 A midline laparotomy was performed to expose the abdominal aorta for the placement of
126 probe. The intestine of the rats was deflected to the right to expose the abdominal aorta.
127 Adjacent fats were removed for proper acoustical coupling. The recorded blood flow was
128 expressed in ml/min.


129 **2.10 Statistical Analysis**

130 Data were expressed as Mean \pm Standard Error of Mean (SEM). Statistical analysis was
131 performed with Graph Pad Prism 5.0. Comparison between mean were done using one way
132 analysis of variance (ANOVA) and differences between means were considered statistically
133 significant at $P=0.05$.

134 **3. RESULTS**

135 **3.1 Effect of L-cysteine Pre-treatment on Gastric Mucus Secretion**

136 Animals pre-treated with various doses of L-cysteine showed significant increase in gastric
137 mucus secretion when compared with the ulcer control group. The groups treated with the
138 standard drug; cimetidine and 500 mg/kg L-cysteine showed the highest secretion of gastric
139 mucus. There was also a dose-dependent increase in gastric mucus secretion in the L-cysteine
140 treated group as shown in Fig 1.



141


142 Figure 1: Effect of Cysteine on mucus secretion in Indomethacin induced ulceration in rats.

143 * $p < 0.05$, ** $p < 0.005$, *** $p < 0.0005$ when compared with ulcer control.

144 3.2 Effect of L-cysteine Prepre-treatment on Antioxidant Enzymes~~antioxidant enzymes~~

145 3.2.1 Superoxide ~~dismutase~~Dismutase

146 The levels of superoxide dismutase obtained from this study are presented in Fig. 2. There
 147 was a significant increase in super oxide dismutase levels in all the L-cysteine and cimetidine
 148 pre-treated animals when compared with the control.




149

150 Figure 2: Effect of L-cysteine on Superoxide Dismutase (SOD) in Indomethacin-induced
 151 ulceration in rats. * $p < 0.05$, ** $p < 0.005$, when compared with ulcer control.

152 3.2.2 Lipid Peroxidation

153 Figure (-3) shows gastric mucosal malondialdehyde (MDA) levels recorded in L-cysteine
 154 pre-treated animals. All the pre-treated animals showed significant decrease in lipid
 155 peroxidation when compared to the animals in the ulcer control group.



156

Figure 3: Effect of Cysteine on Malondialdehyde (MDA) in Indomethacin induced ulceration

* $p < 0.05$, ** $p < 0.005$ when compared with ulcer control.

3.3 Effect of L-cysteine on Gastric Nitric Oxide Level

The results obtained from the nitric oxide study are presented in Figure (4). In this study, pre-treatment with L-cysteine caused a significant increase in nitric oxide concentration similar with the standard drug cimetidine.





Figure 4: Effect of L-cysteine on Nitric Oxide activity in Indomethacin induced ulceration

* $p < 0.05$ when compared with ulcer control.

3.4 Effect of L-cysteine pre-treatment on gastric blood flow in indomethacin-induced ulceration in rats

The gastric blood flow was significantly increased in all the treated groups compared to the ulcer control group as shown in Figure (- 5).



172

173 Figure 5: Effect of Cysteine on Gastric blood flow in indomethacin-induced ulceration.

174 *p<0.05 when compared with ulcer control.

175 3.5 Effect of L-cysteine Pre-treatment on Mean Ulcer Score

176 The mean ulcer score recorded in this study is presented in [table-Table \(1\)](#). The ulcer control
 177 group had a mean ulcer score of $39.5 \pm 7.9 \text{ mm}^2$, which was significantly reduced in
 178 all the L-cysteine treated groups in a dose-dependent manner.

179 Table 1: [effect-Effect](#) of L-cysteine pretreatment on mean ulcer score-

groups	Mean ulcer score (mm ²)
Control	39.5±7.9
L-cysteine (100 mg/kg)	9.5±1.9*
L-cysteine (300 mg/kg)	7.5±1.5*
L-cysteine (500 mg/kg)	4.5±0.9**
Cimetidine	7.0±1.4*

180 *p<0.05 when compared with ulcer control.

4. DISCUSSION

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat musculoskeletal disorders, and are used almost routinely long term by patients with rheumatoid arthritis but has been associated with development of gastric ulcers [19]. It has been demonstrated that NSAIDs (e.g. indomethacin) cause peptic ulceration by a combination of direct effects in the mucous barrier and by local and systemic inhibition of the prostaglandin system. The inhibition of endogenous prostaglandins (PGs) and related compounds, decreases gastric mucosal blood flow, and carbonate synthesis as well as increasing susceptibility to mucosal injury and gastric ulceration [20, 21]. In addition, sequel to the acidic nature of indomethacin [22], it enhances lipid peroxidation and generation of free radicals in the gastric mucosa [23] thereby leading to oxidative damage [24]. Thus, NSAIDs given orally or systemically will cause damage to gastric protective mechanisms, allowing gastric acid to penetrate to submucous structures and thus cause ulceration. Therefore, strategies to protect the gastric mucosa from this offensive agent has been of immense interest to various scientists.

The importance of increased mucus strength and quantity in protecting the regenerating gastric epithelium has been established [25, 26]. Gastric mucus is the first protective barrier in the gastric epithelium that prevents the actions of free radical on the stomach mucosal [27] which could lead to the formation of ulcers [28]. Hydrophobicity play a significant role in protecting the gastric membrane against noxious agents in the lumen [29] as the protective property of the mucus barrier depends not only on the gel structure but also on the amount or thickness of the layer covering the mucosal surface [30]. In this present study, there was an increase in the gastric mucus secretion in the group of animal pre-treated with L-cysteine, which implies that L-cysteine has a promising potential in ameliorating indomethacin- induce peptic ulcer. This report is in agreement with the earlier work carried out by [31], where it was reported that gastric mucus secretion increased in the gastric mucosa of animals treated

206 with aqueous extract of *Eremomastax speciose* against indomethacin-induced ulceration.
207 Allen and Flemstrom reported that an increase in the gastric mucus secretion in stomach
208 confers double protection on the gastric mucosal as it prevents physical damage by acting as
209 a lubricant and chemical damage by sequestering bicarbonate and forming a pH gradient
210 against the proteolytic and acid nature of gastric juice [32].

211 It has been reported that biochemical with antioxidant properties exerts gastroprotective
212 function [33]. Studies have demonstrated that these compounds can scavenge free radicals
213 and are also involve in inhibition of lipid peroxidation, mucus production, decrease of
214 histamine levels and inhibition of gastric acid secretion [34, 35]. Studies have demonstrated
215 that L-cysteine supplementation in rats reduces reactive oxygen species (ROS) thereby
216 demonstrating its antioxidant property [36, 37] and also contains sulfhydryl group which are
217 is a precursors of hydrogen sulfide [38] that mediates various biological functions.

218 In this study, the antioxidant activity of L-cysteine against indomethacin-induced ulcer in rats
219 was observed to determine the possible mechanism of action of this amino acid. L-cysteine
220 mediates its protective role against indomethacin-induced ulcer by reducing the level of
221 malondialdehyde (marker for oxidative stress) and also enhancing the superoxide dismutase
222 activity (antioxidant enzyme). Antioxidant compounds are able to protect the gastric mucosa
223 by binding to acetylcholine muscarinic receptors inhibiting acid secretion [39] and
224 attenuating blood flow, thereby diminishing the hemorrhagic lesions [40].

225 In this study, it was confirmed that the standard drug cimetidine caused a significant increase
226 in nitric oxide. Similar result was recorded when the animals were pre-treated with L-cysteine
227 compared with the control group. Nitric oxide is one of the most important defensive
228 endogenous agents in the gastric mucosa [41]. It is essentially important in the regulation of
229 gastric blood flow and also increases mucus secretion in the gastric mucosa [42]. It inhibits

230 the activation of leukocytes within the microcirculation, and inhibits the inherent release of
231 reactive oxygen metabolites and proteases [43]. On the other hand, suppression of NO
232 production has been reported to delay healing process and this effect was accompanied by a
233 decrease in the gastric blood flow, mucosal growth parameters and attenuated angiogenic
234 response [44]. Also, data obtained from in vitro and in vivo studies suggested that nitric oxide
235 exerts an anti-apoptotic effect on rat gastrointestinal mucosal cells [45]. In addition, L-
236 cysteine contains sulfhydryl group (SH) and serves as a precursor of hydrogen sulphide.
237 Hydrogen sulphide is a potent mediator of vascular smooth muscle relaxation, exhibiting
238 anti-inflammatory activities and ~~contribute~~ contributing to gastric mucosal defense [46]. The
239 SH groups are also responsible for increasing the production of and maintaining mucus
240 stability, through the disulfide bridges, and are involved in maintaining gastric integrity,
241 thereby limiting the production of free radicals involved in tissue damage [47]. The relatively
242 high concentrations of SH have been implicated as in gastroprotection [48].

243 In this study, pre-treatment with L-cysteine caused a significant reduction in the mean ulcer
244 score. The percentage ulcer inhibition in animal pre-treated with L-cysteine were comparable
245 to the standard drug cimetidine and appears to be dose-dependent. Cimetidine is a histamine
246 H₂ receptor antagonist which markedly inhibits gastric acid secretion [49, 50]. This supports
247 the earlier study that cimetidine significantly reduces the effect of NSAIDs-induced peptic
248 ulcer [51]. Thus, L-cysteine could also exert its anti-ulcerogenic effect via the inhibition of
249 H₂ receptors in the gastric epithelia cells.

250 Despite the potent therapeutic effect of non-steroidal anti-inflammatory drugs (NSAIDs), it
251 has been classically established that NSAIDs, such as indomethacin, significantly reduces
252 prostaglandin levels and blood flow to gastric mucosa and thus are considered ulcerogenic
253 agents in long-term use [52]. Therefore, it ~~It is therefore~~ important to assess the

gastroprotective effects of different doses of L- cysteine against indomethacin-induced gastric ulcer. ~~As shown in Fig. 5, pre treatment with L cysteine caused a significant increase in gastric blood flow compared to the vehicle treated ulcerated group.~~ The increase in gastric blood flow facilitated by L-cysteine contributes to protection by supplying the mucosa with oxygen and HCO_3^- , and by removing H^+ and toxic agents diffusing from the lumen into the mucosa. Thus, the results showed that L-cysteine has anti-ulcer potential against different ulcerogenic agents which may be due to the high sulfhydryl content of this amino acid.

5. CONCLUSION

The result from this study shows that L-cysteine possess antiulcer activities which can be attributed to its antioxidant properties, its ability to enhance gastric mucus secretion as well as its sulfhydryl content. L-cysteine which is usually taken as a supplement might ~~therefore~~ be beneficial to people with peptic ulcer disease.

Ethical Disclaimer:

As per international standard or university standard written ethical permission has been collected and preserved by the authors.

6. REFERENCES

1. Malfertheiner P, Francis KL, Kenneth EL. Peptic ulcer disease. The Lancet. 2009; 374(9699):1449-61.
2. Venkateswara C, Venkataramana K. A pharmacological review on natural antiulcer agents. Journal of pharmacognosy. 2013; 4(3):1118-31.
3. Drini M. Peptic ulcer disease and non-steroidal anti-inflammatory drugs. Australian Prescriber 2017; 40(3): 91–93.

- 277 4. Schubert ML. Gastric secretion. *Current Opinion in Gastroenterology* 2014; 30(6):578–
278 582.
- 279 5. Yadav SK, Adhikary B, Bandyopadhyay SK, Chattopadhyay S. Inhibition of TNF-
280 alpha, and NF-kappa B and JNK pathways accounts for the prophylactic action of the
281 natural phenolic, allylpyrocatechol against indomethacin gastropathy. *Biochimica et*
282 *Biophysica Acta* 2013; 1830(6):3776-3786.
- 283 6. Ohyama, K, Shiokawa A, Ito K, Masuyama R, Ichibangase T, Kishikawa N, et al.
284 Toxicoproteomic analysis of a mouse model of nonsteroidal anti-inflammatory drug-
285 induced gastric ulcers. *Biochem. Biophys. Res. Commun* 2012; 420(1): 210-215.
- 286 7. Zanardo RC, Brancalone V, Distrutti E, Fiorucci S, Cirino G, Wallace J L. Hydrogen
287 sulfide is an endogenous modulator of leukocyte-mediated inflammation. *FASEB*
288 *Journal* 2006; 20; 2118–2120.
- 289 8. Bhatia M, Sidhapuriwala J, Moochhala SM, Moore PK. Hydrogen sulphide is a
290 mediator of carrageenan-induced hind paw oedema in the rat. *Br J Pharmacol* 2005;
291 145(2): 141–144.
- 292 9. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second
293 hundred years. *Gastroenterology* 1997; 112, 1000–1016.
- 294 10. Atalay F, Odabasoglu F, Halici M, Cadirci E, Aydin O, Halici Z, Cakir A. N-Acetyl
295 Cysteine Has Both Gastro-Protective and Anti-Inflammatory Effects in Experimental
296 Rat Models: Its Gastro-Protective Effect Is Related to Its In Vivo and In Vitro
297 Antioxidant Properties. *Journal of Cellular Biochemistry* 2015; 117(2): 308–319.
- 298 11. National Institute of Health. NIH consensus Development program. NIH statement
299 1996; 14(1):1-38.
- 300 12. Oluwole FS, Bolarinwa AF. Experimental peptic ulceration during oestrous cycle. *Nig.*
301 *J. Physiol Sci.* 1991; 7(1):18-21.

- 302 13. Alphin RS, Ward JW. Actions of Hexopyrronium Bromide on gastric secretion in dogs
303 and Ulceration in rats. Biomed. Environ Sci. 1967; 6(1):488-95.
- 304 14. Elegbe RA, Bambgose SOA. Protective dietary factors in experimental ulceration-
305 Studies on some Nigerian cereal and tubers. Postgrad. Med. 1976; 52(607):258- 63.
- 306 15. Misra HP, Fridovich I. The role of superoxide anion in the antioxidation of epinephrine
307 and a simple assay for superoxide dismutase. J. Biol Chem. 1972; 25(10):3170-75.
- 308 16. Varshney R, Kale RK. Effects of calmodulin antagonist on radiation induced lipid
309 peroxidation in microsomes. Int J Radiat Biol. 1990; 58(5):733-43.
- 310 17. Corney IN, Dhuley JN, Naik SR. Protection by rhinax in various models of ulceration in
311 rats. J. Ethnopharmacol. 1998; 197463: 219-2125.
- 312 18. Moshage H, Kok B, Huiezena JR, Jansen PL. Nitrite and nitrate determinations in
313 plasma: A critical evaluation. Clin Chem. 1995; 41(6):892-96.
- 314 19. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy. Arch Intern
315 Med 1987; 147(2): 2093-100.
- 316 20. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of
317 cyclooxygenase inhibition and gastric hyper motility. World J Gastroenterol. 2012;
318 14(18):2147-60.
- 319 21. Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current Perspectives in
320 NSAID-Induced Gastropathy. Mediators Inflamm. 2013; 1-11.
- 321 22. Tarnawski A, Brzozowski T, Sarfeh IJ, Krause WJ, Ulich TR, Gergely H, et al.
322 Prostaglandin protection of human isolated gastric glands against indomethacin and
323 ethanol injury. Evidence for direct cellular action of prostaglandin. J Clin Invest. 1988;
324 81(4): 1081-1089.

- 325 23. Suleyman H, Albayrak A, Bilici M, Cadirci E, Halici Z. Different mechanisms in
326 formation and prevention of indomethacin-induced gastric ulcers. *Inflammation* 2010;
327 33:224-34.
- 328 24. Potrich FB, Allemand A, Silva LM, Dos Santos AC, Baggio CH, Freitas
329 CS. Antiulcerogenic activity of hydroalcoholic extract of *Achillea millefolium* L:
330 Involvement of the antioxidant system. *J Ethnopharmacol* 2010; 130(1):85-92.
- 331 25. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench
332 to bedside, *Gastroenterology* 2008; 135(1): 41–60.
- 333 26. Polo CM, Moraes TM, Pellizzon CH, Marques MMO, Rocha LRM, Hiruma-Lima CA.
334 Gastric ulcers in middle-aged rats: the healing effect of essential oil from citrus
335 aurantium L. (Rutaceae), *Evidence-Based Complementary and Alternative Medicine*
336 2012; 51(8): 1-8.
- 337 27. Gupta D, Du Y, Piluek J, Jakub AM, Buella KA, Abbott A, et al. Pyruvate ameliorates
338 endotoxin-induced corneal inflammation. *Investig. Ophthalmol. Vis. Sci.* 2012;
339 53(10):6589–99.
- 340 28. Yandrapu H, Sarosiek J. Protective factors of the gastric and duodenal mucosa: an
341 overview, *Current Gastroenterology Reports* 2015; 17(24): 1-8.
- 342 29. Asante M, Ahmed H, Patel P, Davis T, Finlayson C, Mendall M, Northfield T. Gastric
343 mucosal hydrophobicity in duodenal ulceration: role of *Helicobacter pylori* infection
344 density and mucus lipids, *Gastroenterology* 1997; 113(2): 449–454.
- 345 30. Penissi A, Piezzi R. Effect of dehydroleucodine on mucus production. A quantitative
346 study. *Digestive Diseases and Sciences*. 1999; 44(4):708-12.
- 347 31. Amang AP, Mezui C, Siwe GT, Emakoua J, Mbah G, Nkwengoua EZ, et al. Healing
348 and Antisecretory Effects of Aqueous Extract of *Eremomastax speciosa* (Acanthaceae)
349 on Unhealed Gastric Ulcers. *Biomed Res International*. 2017;1924320: 1-11.

- 350 32. Allen A, Flemstrom G. Gastroduodenal mucus bicarbonate barrier: protection against
351 acid and pepsin,” American Journal of Physiology-Cell Physiology 2005; 288(1):C1–
352 C19.
- 353 33. Alvarez-Suarez JM, Dekanski D, Ristić S, Radonjić NV, Petronijević ND, Giampieri F,
354 et al. Strawberry Polyphenols Attenuate Ethanol-Induced Gastric Lesions in Rats by
355 Activation of Antioxidant Enzymes and Attenuation of MDA Increase. PLoS One.
356 2011; 6(10):1-11.
- 357 34. Priya G, Parminder N, Jaspreet S. Oxidative stress induced ulcer protected by natural
358 antioxidants: a review. International research journal of pharmacy 2012; 3(5): 76-81.
- 359 35. Repetto MG, Llesuy SF. Antioxidant properties of natural compounds used in popular
360 medicine for gastric ulcers. Braz J Med Biol Res, May 2002; 35(5):523-534.
- 361 36. Pravina P. Cysteine –master antioxidant. International journal of pharmaceutical,
362 chemical and biological sciences. IJPCBS 2013; 3(1):143-149.
- 363 37. Shimamoto K, Hayashi H, Taniai E, Morita R, Imaoka M, Ishii Y, et al. Antioxidant N-
364 acetyl-L-cysteine (NAC) supplementation reduces reactive oxygen species (ROS)-
365 mediated hepatocellular tumor promotion of indole-3-carbinol (I3C) in rats. J Toxicol
366 Sci. 2011; 36(6):775-86.
- 367 38. Shibuya N, Koike S, Tanaka M, Ishigami-Yuasa M, Kimura Y, Ogasawara Y, et al. A
368 novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian
369 cells. Nature Commun 2013; 4:1-7.
- 370 39. Toma, W, Hirumu-Lima CA, Guerrero RO, Souza AR. Preliminary studies on
371 Mamea Americana L (Guttiferae) bark/latex extract point to an effective anti-ulcer
372 effect on gastric ulcer models in mice. Phytomedicine 2005; 12(1): 345-50.
- 373 40. O'Brien P, Carrasco-Pozo C, Speisky H. Boldine and its antioxidant or health-
374 promoting properties. Chem Biol Interact. 2006; 159(1):1-17.

- 375 41. El-Abhar HS. Coenzyme Q10: a novel gastroprotective effect via modulation of
376 vascular permeability, prostaglandin E2, nitric oxide and redox status in indomethacin-
377 induced gastric ulcer model. *European Journal of Pharmacology* 2010; 649(1): 314–
378 319, 2010.
- 379 42. Kwiecień S, Brzozowski T, Konturek PCH, Konturek SJ. The role of reactive oxygen
380 species in action of nitric oxide-donors on stress-induced gastric mucosal lesions.
381 *Journal of physiology and pharmacology* 2002; 53(4): 761-773.
- 382 43. Niv Y, Banić M. Gastric barrier function and toxic damage, *Digestive Diseases* 2014;
383 32(3): 235–242.
- 384 44. Konturek SJ, Brzozowski T, Majka J, PytkoPolonczyk J, Stachura J. Inhibition of nitric
385 oxide synthase delays the healing of chronic gastric ulcers. *EurJ Pharmacol* 1993;
386 239:215- 217.
- 387 45. Kochar NI, Chandewal AV, Bakal RL, Kochar PN. Nitric Oxide and the
388 Gastrointestinal Tract. *International Journal of Pharmacology* 2011; 7 (1):
389 31-39.
- 390 46. Wallace JL, Ferraz JGP, Muscara NM. Hydrogen Sulfide: An Endogenous Mediator of
391 Resolution of Inflammation and Injury. *Antioxid Redox Signal*. 2012; 17(1): 58–67.
- 392 47. Caldas GFR, Oliveira ARD, Araújo AV, Lafayette SSL, Albuquerque GS, Silva-Neto
393 JC, et al. Gastroprotective mechanisms of the monoterpene 1,8-cineole
394 (eucalyptol) *PLoS One* 2015; 10(8): 1-17.
- 395 48. Zakaria ZA, Balan T, Azemi AK. Mechanism(s) of action underlying the
396 gastroprotective effect of ethyl acetate fraction obtained from the crude methanolic
397 leaves extract of *Muntingia calabura*,” *BMC Complementary and Alternative Medicine*
398 2016; 16(1): 78-83.

- 399 49. Pounder RE, Williams JG, Russell CG. Inhibition of food stimulated gastric acid
400 secretion by cimetidine. *Gut* 1976; 17(3):161-168.
- 401 50. Richardson CT, Walsh JH, Hicks MI. The effect of cimetidine, a new histamine H2-
402 receptor antagonist, on meal-stimulated acid secretion, serum gastrin, and gastric
403 emptying in patients with duodenal ulcer, *Gastroenterology* 1976; 71(1):19-23.
- 404 51. Davies J, Collins AJ, Dixonu AJ. The influence of cimetidine on peptic ulcer in patients
405 with arthritis taking anti-inflammatory drugs. *British Journal of Rheumatology* 1986;
406 25(1):54-58.
- 407 52. Mózsik G. Gastric cytoprotection 30 years after its discovery by André Robert: a
408 personal perspective. *Inflammopharmacology*. 2010; 18(5):209-21.